RU93058534A - APPLICATION OF TETRAHYDROCARBAZOLE DERIVATIVES AS 5-NT * 001 RECEPTOR ANTAGONISTS, TETRAHYDROCARBAZOLE DERIVATIVES, METHOD FOR PRODUCING THERAPY, METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITION - Google Patents
APPLICATION OF TETRAHYDROCARBAZOLE DERIVATIVES AS 5-NT * 001 RECEPTOR ANTAGONISTS, TETRAHYDROCARBAZOLE DERIVATIVES, METHOD FOR PRODUCING THERAPY, METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONInfo
- Publication number
- RU93058534A RU93058534A RU93058534/14A RU93058534A RU93058534A RU 93058534 A RU93058534 A RU 93058534A RU 93058534/14 A RU93058534/14 A RU 93058534/14A RU 93058534 A RU93058534 A RU 93058534A RU 93058534 A RU93058534 A RU 93058534A
- Authority
- RU
- Russia
- Prior art keywords
- tetrahydrocarbazole derivatives
- alkyl
- treatment
- pharmaceutical composition
- application
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-carbazole Chemical class N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 150000002829 nitrogen Chemical group 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N Azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- -1 nitro, hydroxy Chemical group 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Claims (1)
в котором R1 представляет водород, галоген, трифторметил, нитро, гидрокси, C1 - 6алкил, C1 - 6алкокси, арил C1 - 6алкокси, -CO2R4, -/CH2/n CN, -/CH2/nCONR5R6, -/CH2/n SO2NR5R6; C1 - 6алканоиламино/CH2/n, или C1 - 6алкилсульфониламино/CH2/n; R4 представляет водород, C1 - 6алкил или арил C1 - 6алкил; R5 и R6 каждый независимо представляют водород или C1 - 6алкил, или R5 и R6 вместе с атомом азота, к которому они присоединены, образуют кольцо; n представляет 0, 1 или 2; R2 и R3 каждый независимо представляют водород, C1 - 6алкил или бензил или вместе с атомом азота, к которому они присоединены, образуют кольцо пирролидино, пиперидино или гексагидроазепино, или его физиологически приемлемой соли в получении лекарства для лечения состояния, в котором показан 5-HT1-подобный антагонист, например мигрени. Описываются также новые соединения формулы, способы их получения и фармацевтические композиции, содержащие их.The use of a compound of the general formula
wherein R 1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C 1 - 6 alkyl, C 1 - 6 alkoxy, aryl C 1 - 6 alkoxy, -CO 2 R 4, - / CH 2 / n CN, - / CH 2 / nCONR 5 R 6 , - / CH 2 / n SO 2 NR 5 R 6 ; C 1 - 6 alkanoylamino / CH 2 / n, or C 1 - 6 alkylsulfonylamino / CH 2 / n; R 4 is hydrogen, C 1 - 6 alkyl or aryl C 1 - 6 alkyl; R 5 and R 6 each independently represent hydrogen or C 1 - 6 alkyl, or R 5 and R 6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; R 2 and R 3 each independently represent hydrogen, C 1 - 6 alkyl or benzyl or together with the nitrogen atom to which they are attached form a ring of pyrrolidine, piperidine or hexahydroazepine, or a physiologically acceptable salt thereof in the preparation of a medicament for treating a condition, wherein a 5-HT 1 -like antagonist is shown, for example, migraine. Also described are new compounds of the formula, methods for their preparation and pharmaceutical compositions containing them.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919113802A GB9113802D0 (en) | 1991-06-26 | 1991-06-26 | Medicaments |
GB9113802.4 | 1991-06-26 | ||
PCT/GB1992/001082 WO1993000086A1 (en) | 1991-06-26 | 1992-06-17 | Use of tetrahydrocarbazone derivatives as 5ht1 receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
RU93058534A true RU93058534A (en) | 1997-02-10 |
RU2137474C1 RU2137474C1 (en) | 1999-09-20 |
Family
ID=10697363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU93058534A RU2137474C1 (en) | 1991-06-26 | 1992-06-17 | Method of treatment of state where 5ht1-like agonist, derivative of tetrahydrocarbazole is required, method of its synthesis, pharmaceutical composition showing activity of agonist of 5ht1-like receptors |
Country Status (35)
Country | Link |
---|---|
US (2) | US5464864A (en) |
EP (1) | EP0591280B1 (en) |
JP (1) | JP3261502B2 (en) |
KR (1) | KR100251571B1 (en) |
CN (1) | CN1034072C (en) |
AP (1) | AP344A (en) |
AT (1) | ATE170746T1 (en) |
BR (2) | BR9206237A (en) |
CA (1) | CA2113726C (en) |
CZ (3) | CZ282061B6 (en) |
DE (2) | DE69226953T2 (en) |
DK (1) | DK0591280T3 (en) |
FI (1) | FI103967B1 (en) |
GB (1) | GB9113802D0 (en) |
HK (1) | HK1014669A1 (en) |
HU (1) | HU218907B (en) |
IE (1) | IE922062A1 (en) |
IL (4) | IL117105A (en) |
LU (1) | LU90939I2 (en) |
MA (1) | MA22563A1 (en) |
MX (1) | MX9203444A (en) |
NL (1) | NL300103I2 (en) |
NO (2) | NO304774B1 (en) |
NZ (1) | NZ243288A (en) |
PL (3) | PL169392B1 (en) |
PT (1) | PT100620B (en) |
RU (1) | RU2137474C1 (en) |
SA (1) | SA92130141B1 (en) |
SG (1) | SG47877A1 (en) |
SI (1) | SI9200125B (en) |
SK (3) | SK280905B6 (en) |
TW (1) | TW214544B (en) |
UA (1) | UA41254C2 (en) |
WO (1) | WO1993000086A1 (en) |
ZA (1) | ZA924658B (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9211277D0 (en) | 1992-05-28 | 1992-07-15 | Glaxo Group Inc | Pharmaceutical compositions |
GB9226566D0 (en) * | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
GB9226530D0 (en) * | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
US5616603A (en) * | 1995-05-26 | 1997-04-01 | Smithkline Beecham Plc | Enantiomers of carbazole derivatives as 5-HT1 -like agonists |
US5618948A (en) * | 1995-05-26 | 1997-04-08 | Smithkline Beecham P.L.C. | Process for preparing an enantiomer of a carbazole derivative |
ES2151993T3 (en) * | 1995-06-23 | 2001-01-16 | Lilly Co Eli | 1,2,3,4-TETRAHIDRO-9H-CARBAZOLES 6-SUBSTITUTES AND 10H-CICLOHEPTA (7,6-B) INDOLES 7-SUBSTITUTES. |
US5917054A (en) * | 1995-07-18 | 1999-06-29 | Smithkline Beecham P.L.C. | Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists |
US5708187A (en) * | 1996-06-27 | 1998-01-13 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists |
US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
GB9723061D0 (en) * | 1997-10-31 | 1998-01-07 | Vanguard Medica Ltd | Medicaments |
US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
US6066092A (en) * | 1997-11-06 | 2000-05-23 | Cady; Roger K. | Preemptive prophylaxis of migraine device and method |
GB9808069D0 (en) * | 1998-04-16 | 1998-06-17 | Vanguard Medica Ltd | Novel processes |
GB9817911D0 (en) * | 1998-08-17 | 1998-10-14 | Vanguard Medica Ltd | New use |
US6685951B2 (en) | 2001-07-05 | 2004-02-03 | R. T. Alamo Ventures I, Inc. | Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine |
US20030198669A1 (en) * | 2001-07-05 | 2003-10-23 | R.T. Alamo Ventures I, Llc | Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine |
US20030017175A1 (en) * | 2001-07-05 | 2003-01-23 | R.T. Alamo Ventures I, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
DK1537113T5 (en) | 2002-06-21 | 2011-01-10 | Suven Life Sciences Ltd | Arylalkyl indoles with serotonin receptor affinity useful as therapeutic agents, processes for their preparation and pharmaceutical compositions containing them |
CA2490254C (en) | 2002-06-21 | 2011-11-01 | Suven Life Sciences Limited | Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
NZ572186A (en) | 2002-11-28 | 2010-02-26 | Suven Life Sciences Ltd | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
BRPI0315958B8 (en) | 2002-11-28 | 2021-05-25 | Suven Life Sciences Ltd | compound, pharmaceutical composition, process for preparing a compound, new intermediates and use of the compound |
PT1581538E (en) | 2002-12-18 | 2007-05-31 | Suven Life Sciences Ltd | Tetracyclic 3-substituted indoles having serotonin receptor affinity |
KR101411820B1 (en) * | 2006-08-07 | 2014-06-24 | 액테리온 파마슈티칼 리미티드 | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives |
JP2010522135A (en) | 2006-10-09 | 2010-07-01 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
EP2120875B1 (en) | 2007-02-11 | 2018-07-11 | Map Pharmaceuticals Inc. | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
US20090069399A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched frovatriptan |
JP5714910B2 (en) | 2008-01-09 | 2015-05-07 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
WO2010073253A1 (en) * | 2008-12-22 | 2010-07-01 | Natco Pharma Limited | Method for preparing an optically active frovatriptan |
CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
US9204906B2 (en) | 2009-10-22 | 2015-12-08 | Nuvasive, Inc. | Posterior cervical fusion system and techniques |
US10098674B2 (en) | 2009-10-22 | 2018-10-16 | Nuvasive, Inc. | System and method for posterior cervical fusion |
WO2013016223A2 (en) | 2011-07-22 | 2013-01-31 | The University Of Chicago | Treatments for migraine and related disorders |
CA2895816C (en) | 2012-12-21 | 2021-02-23 | Map Pharmaceuticals, Inc. | 8'-hydroxy-dihydroergotamine compounds and compositions |
EP2816030A1 (en) | 2013-06-20 | 2014-12-24 | Duke Chem, S. A. | Process for the preparation of frovatriptan and its enantiomer |
GB201312768D0 (en) | 2013-07-17 | 2013-08-28 | Ge Healthcare Ltd | Work-up procedure |
US10179109B2 (en) | 2016-03-04 | 2019-01-15 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates |
EP3766483A1 (en) | 2019-07-19 | 2021-01-20 | BioPharma Synergies, S. L. | Orodispersible powder composition comprising a triptan |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3642816A (en) * | 1967-08-10 | 1972-02-15 | Sterling Drug Inc | 3-acetamido-1 2 3 4-tetrahydrocarbazole |
US4062864A (en) * | 1968-01-24 | 1977-12-13 | Sterling Drug Inc. | 3-Hydroxy carbazole derivatives |
US3959309A (en) * | 1968-01-24 | 1976-05-25 | Sterling Drug Inc. | 3-Amido-1,2,3,4-tetrahydrocarbazoles |
US3592824A (en) * | 1970-03-12 | 1971-07-13 | Miles Lab | 3-substituted amino-1,2,3,4-tetrahydrocarbazoles |
US4172834A (en) * | 1971-08-16 | 1979-10-30 | Sterling Drug Inc. | 3-Amino-tetrahydrocarbazoles |
BE787537A (en) * | 1971-08-16 | 1973-02-14 | Sterling Drug Inc | TETRAHYDROCARBAZOLES |
US4257952A (en) * | 1977-06-06 | 1981-03-24 | Sterling Drug Inc. | 3-Amino-tetrahydrocarbazoles |
US4254134A (en) * | 1978-03-17 | 1981-03-03 | Endo Laboratories, Inc. | Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles |
EP0115607A1 (en) * | 1983-01-04 | 1984-08-15 | MERCK PATENT GmbH | Tetrahydrocarbazol derivatives |
-
1991
- 1991-06-26 GB GB919113802A patent/GB9113802D0/en active Pending
-
1992
- 1992-06-17 JP JP51108692A patent/JP3261502B2/en not_active Expired - Lifetime
- 1992-06-17 KR KR1019930704055A patent/KR100251571B1/en not_active IP Right Cessation
- 1992-06-17 RU RU93058534A patent/RU2137474C1/en active Protection Beyond IP Right Term
- 1992-06-17 PL PL92301883A patent/PL169392B1/en unknown
- 1992-06-17 UA UA93002251A patent/UA41254C2/en unknown
- 1992-06-17 PL PL92311304A patent/PL171034B1/en unknown
- 1992-06-17 US US08/167,846 patent/US5464864A/en not_active Expired - Lifetime
- 1992-06-17 PL PL92307118A patent/PL169410B1/en unknown
- 1992-06-17 CZ CZ961505A patent/CZ282061B6/en not_active IP Right Cessation
- 1992-06-17 DE DE69226953T patent/DE69226953T2/en not_active Expired - Lifetime
- 1992-06-17 BR BR9206237A patent/BR9206237A/en not_active Application Discontinuation
- 1992-06-17 WO PCT/GB1992/001082 patent/WO1993000086A1/en active IP Right Grant
- 1992-06-17 EP EP92912379A patent/EP0591280B1/en not_active Expired - Lifetime
- 1992-06-17 SK SK1319-93A patent/SK280905B6/en not_active IP Right Cessation
- 1992-06-17 SG SG1996004938A patent/SG47877A1/en unknown
- 1992-06-17 CZ CZ961506A patent/CZ282327B6/en not_active IP Right Cessation
- 1992-06-17 CZ CS932861A patent/CZ282083B6/en not_active IP Right Cessation
- 1992-06-17 DE DE2002199042 patent/DE10299042I2/en active Active
- 1992-06-17 SK SK1685-98A patent/SK280907B6/en not_active IP Right Cessation
- 1992-06-17 DK DK92912379T patent/DK0591280T3/en active
- 1992-06-17 AT AT92912379T patent/ATE170746T1/en active
- 1992-06-17 CA CA002113726A patent/CA2113726C/en not_active Expired - Lifetime
- 1992-06-17 SK SK1054-98A patent/SK280906B6/en not_active IP Right Cessation
- 1992-06-17 HU HU9303731A patent/HU218907B/en active IP Right Revival
- 1992-06-24 PT PT100620A patent/PT100620B/en not_active IP Right Cessation
- 1992-06-24 ZA ZA924658A patent/ZA924658B/en unknown
- 1992-06-24 NZ NZ243288A patent/NZ243288A/en not_active IP Right Cessation
- 1992-06-24 MA MA22853A patent/MA22563A1/en unknown
- 1992-06-25 IL IL117105A patent/IL117105A/en not_active IP Right Cessation
- 1992-06-25 IL IL102322A patent/IL102322A/en not_active IP Right Cessation
- 1992-06-25 TW TW081104991A patent/TW214544B/zh not_active IP Right Cessation
- 1992-06-25 AP APAP/P/1992/000403A patent/AP344A/en active
- 1992-06-25 IL IL11710596A patent/IL117105A0/en unknown
- 1992-06-25 IL IL117104A patent/IL117104A/en not_active IP Right Cessation
- 1992-06-25 CN CN92108831A patent/CN1034072C/en not_active Expired - Lifetime
- 1992-06-26 SI SI9200125A patent/SI9200125B/en unknown
- 1992-06-26 MX MX9203444A patent/MX9203444A/en unknown
- 1992-07-01 IE IE206292A patent/IE922062A1/en not_active IP Right Cessation
- 1992-10-04 SA SA92130141A patent/SA92130141B1/en unknown
-
1993
- 1993-12-23 NO NO934759A patent/NO304774B1/en not_active IP Right Cessation
- 1993-12-23 FI FI935842A patent/FI103967B1/en not_active IP Right Cessation
-
1995
- 1995-05-15 US US08/442,719 patent/US5637611A/en not_active Expired - Lifetime
-
1997
- 1997-05-06 BR BR1100460-6A patent/BR1100460A/en active IP Right Grant
-
1998
- 1998-12-28 HK HK98116054A patent/HK1014669A1/en not_active IP Right Cessation
-
2002
- 2002-07-24 LU LU90939C patent/LU90939I2/en unknown
- 2002-10-14 NL NL300103C patent/NL300103I2/en unknown
-
2005
- 2005-05-03 NO NO2005011C patent/NO2005011I2/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU93058534A (en) | APPLICATION OF TETRAHYDROCARBAZOLE DERIVATIVES AS 5-NT * 001 RECEPTOR ANTAGONISTS, TETRAHYDROCARBAZOLE DERIVATIVES, METHOD FOR PRODUCING THERAPY, METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITION | |
UA41254C2 (en) | TETRAHYDROCARBAZOLE DERIVATIVE OR ITS SALT, SOLVATE OR HYDRATE AS AN AGONIST OF 5-HT <sub> 1 </sub> -SILE RECEPTOR, METHOD OF THEIR DETERMINATION | |
RU2214400C2 (en) | Derivatives of 1-[(1-substituted-4-piperidinyl)- methyl]-4-piperidine, methods for their preparing, pharmaceutical composition based on thereof and intermediate substances | |
RU2000129161A (en) | DERIVATIVE 1 - [(1-SUBSTITUTED-4-PIPERIDINYL) METHYL] -4-PIPERIDINE, METHOD FOR ITS PRODUCTION, PHARMACEUTICAL COMPOSITION CONTAINING THE INDICATED COMPOUND, AND THE INTERMEDIATE PRODUCT | |
JP2003530345A (en) | Pharmaceutical composition for the treatment of acute, chronic pain and / or neuropathic pain and migraine | |
RU98105169A (en) | DERIVATIVES 8-AZABICYCLO [3.2.1] OCT-2-ENA, THEIR RECEIVING AND APPLICATION | |
RU92004336A (en) | WATER-SOLUBLE DERIVATIVES OF CAMPTOTECINE, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING ENZYM TOOPOISOMERS, INTERMEDIATE PRODUCTS | |
RU98117314A (en) | TROPANIC DERIVATIVES, THEIR PRODUCTION AND APPLICATION | |
EA200600811A1 (en) | NEW TETRAHYDROSPIRO {PIPERIDIN-2,7'-PYRROLO [3,2-b] PYRIDINE} DERIVATIVES AND NEW INDOLA DERIVATIVES, APPLICATION FOR THE TREATMENT OF DISORDERS RELATED TO 5-HT-RECEPTOR | |
DE69033915D1 (en) | Xanthine derivatives, processes for their preparation and their pharmaceutical use | |
RU94044671A (en) | Use of nonpeptide antagonists of tachykinin receptors | |
BR0211201A (en) | Compound, process for preparing such compound, use thereof, pharmaceutical composition comprising the same and method for treating a disease in a mammal | |
JP2009526821A (en) | Novel pharmaceutical composition for the treatment of attention deficit hyperactivity disorder | |
JP2608079B2 (en) | Medicine | |
RU94030812A (en) | DERIVATIVES OF PHOSPHONOANATIC ACID, METHOD OF THEIR PRODUCTION AND CONTAINING THESE COMPOUNDS PHARMACEUTICAL COMPOSITIONS | |
US5340826A (en) | Pharmaceutical agents for treatment of urinary incontinence | |
RU98119076A (en) | DERIVATIVES OF 2- (3H) -OXASOLONE AND THEIR APPLICATION AS SOX-2 INHIBITORS | |
AR037611A1 (en) | COMPOUNDS DERIVED FROM AMINO-TETRALINA, ITS USE, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
RU95113434A (en) | Dimethylbenzofurans and dimethylbenzopyrans, their use as 5-ht3-antagonists, method of synthesis, pharmaceutical composition | |
RU2208013C2 (en) | Derivatives of 8-substituted=9h-1,3-dioxol[4,5-h][2,3]- benzodiazepine as inhibitors of ampa/kainate receptor, method for their preparing, pharmaceutical composition based on thereof and method of treatment | |
RU2006104024A (en) | KAPPA-AGONISTS, ESPECIALLY FOR TREATMENT AND / OR PREVENTION OF AN IRRITATED FATIGUE SYNDROME | |
JP2004534758A5 (en) | ||
RU94043786A (en) | Substituted phenylcarbamates and phenylureas, process for preparation thereof and use thereof as 5-nt-antagonists | |
JPH05132430A (en) | Use of glycine/nmda receptor ligand relating to therapy of drug dependence and withdrawal symptoms | |
JPS62424A (en) | Medicinal composition |